In a pooled analysis of the STEP trials, semaglutide produced substantial weight loss and cardiometabolic improvements in adults aged 65 years or older.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/patients-over-65-obesity-respond-well-semaglutide-2026a1000fgu?src=rss
Author :
Publish date : 2026-05-13 13:05:00
Copyright for syndicated content belongs to the linked Source.
